- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00163254
Below Study - Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee
Balloonangioplasty or Stents With ReoPro for Prevention of Subacute Reocclusion in Arteries Below the Knee
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PTA below the knee is limited due to subacute reocclusions and uncertain long-term results. This study is designed as a feasibility trial, which compares the two new treatment modalities: drug eluting stents and GP IIb/IIIa blockade.
Patients with current ulcers (Rutherford 5, or 6) are randomly assigned to one of the treatment groups: [1] ReoPro + Sirolimus coated stent, [2] ReoPro + bare Stent, [3] ReoPro + PTA, [4] PTA without ReoPro. Angiographic control will be at 2 and 6 months with block wise randomisation to the treatment groups.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Tuebingen, Germany, 72076
- University of Tuebingen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a history of peripheral artery disease with below the knee artery occlusion, or stenosis which mandates PTA or stent administration as first treatment modality. The history of peripheral artery occlusion has to at least 6 weeks, and the target vessel occlusion has to be no longer than 5 centimeters in length (corresponding to a maximum of 2 stents per treated lesion). The number of treated lesions per vessel in this study is limited to three. Only the major lesion will be allocated to one of the study groups, the other lesions will be treated by conventional PTA. A documentation of distal outflow (no occlusion until 3 cm above the upper joint ankle) is mandatory
- Severe stage of PAD with ulceration(s) corresponding to Rutherford stage 5 or 6.
Exclusion Criteria:
- Acute limb ischemia
- Subacute ischemia with requires thrombolysis as first treatment modality
- Active bleeding or known bleeding diathesis
- Known severe hepatic or renal disorder (liver cirrhosis, stage B, C or serum creatinine > 2.5 mg%)
- Hyperthyreosis
- Diabetes mellitus treated with metformin
- Known heparin induced thrombocytopenia (HIT, type 2)
- Major surgery, eye surgery or trauma within past 6 weeks
- History of stroke within the previous 2 years, or any stroke with a residual neurological deficit, or other CNS abnormality (e.g., intracranial neoplasm, arteriovenous malformation, or aneurysm), or history of aneurysm repair
- Gastrointestinal or genitourinary bleeding of clinical significance within the previous 6 weeks
- Puncture of a non compressible vessel within past 24 hours
- Administration of oral anticoagulants within the previous 7 days unless prothrombin time is < 1.2 times control (or international normalized ratio [INR] <1.4), or ongoing treatment with oral anticoagulants
- History of bleeding diathesis of platelet count < 100,000/mm3
- Known ReoPro-induced thrombocytopenia
- Arteriovenous malformations or aneurysms
- Severe uncontrolled hypertension (treated sys. BP > 200 mm Hg, diast. BP > 100 mm Hg)
- Known autoimmune disorders
- Patient with vasculitis
- Patient with aspirin intolerance
- Contraindication or known allergic reactions to rapamycin, abciximab or murine proteins
- Co-existent condition associated with a limited life expectancy (e.g., advanced cancer, end-stage congestive heart failure)
- Women of child-bearing potential with a positive pregnancy test
- Patient in prison or any vulnerable patient (soldier,…) as defined in the declaration of Helsinki
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The primary study objective is to demonstrate the superiority of an adjunctive administration of abciximab and drug eluting stents on the rate of subacute reocclusions at day 60 ± 10.
|
Secondary Outcome Measures
Outcome Measure |
---|
Safety analysis
|
The binary restenosis rate (restenosis > 50%) at 6 months
|
The rate of mortality, amputation (including toes), repeat target vessel intervention, and healing of ulcers 2 and 6 months from randomization.
|
Quality of life assessment 2 and at 6 months compared to baseline
|
Change in ankle brachial index (ABI) after the intervention, at 2 and at 6 months.
|
Change in Rutherford stages at 2 and at 6 months compared to baseline.
|
Hospital days for index hospitalization
|
Hospital days for repeat revascularization and amputation at 2 and 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gunnar Tepe, MD, University Hospital Tuebingen
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- btk-1
- D 30.08290
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patients Above 18 Years
-
American University of Beirut Medical CenterMerck Sharp & Dohme LLCCompletedNon-operative Time | General Surgery, Above 18 Years of AgeLebanon
-
Baylor Research InstituteRecruitingHospitalized Patients 18 Years of Age or Older With PainUnited States
-
Wayne State UniversityGlaxoSmithKlineUnknownICU Patients 18 Years or Older.United States
-
AstraZenecaCompletedHealthy Japanese Children Age 7 Years Through 18 YearsJapan
-
Gazi UniversityThe Scientific and Technological Research Council of TurkeyRecruiting
-
University Medical Center GroningenUnknownSolid Organ Tranplant Recipients, 18+ YearsNetherlands
-
Hillel Yaffe Medical CenterUnknownSmoking Woman | 18-60 Years OldIsrael
-
Charles University, Czech RepublicActive, not recruitingHealthy | Age of Probands 18 - 55 YearsCzechia
-
Poznan University of Physical EducationPoznan University of Medical Sciences; National Science Centre, PolandActive, not recruitingHealthy Athletes Aged 18-35 YearsPoland
-
Mid Michigan Health CentersCompletedNo Conditions for This Study. All Male Patients 18 Years of Age or Older Were Administered the LUTS, MSHQ, and Patient Demographics QuestionnaireUnited States
Clinical Trials on abciximab
-
Centocor, Inc.Eli Lilly and CompanyCompletedMyocardial InfarctionUnited States, France, United Kingdom, Belgium, Germany, Spain, Poland, Bulgaria, Romania, Israel, Sweden, Canada, Czech Republic, Argentina, Austria, Denmark, Netherlands, South Africa, Switzerland
-
University of LeipzigCompletedST-elevation Myocardial InfarctionGermany
-
University of LeipzigCompleted
-
Laval UniversityEli Lilly and Company; Cordis Corporation; Quebec Heart InstituteCompletedMyocardial Infarction | IschemiaCanada
-
University of PisaEli Lilly and CompanyCompletedMyocardial InfarctionItaly
-
Olivier F. BertrandEli Lilly and Company; Cordis CorporationCompletedMyocardial Infarction | IschemiaCanada
-
Università degli Studi di FerraraCompletedAcute Coronary SyndromeItaly
-
Azienda Sanitaria OspedalieraCardiologia 2 - Emodinamica - Ospedale Maggiore, Novara, ItalyTerminatedMyocardial Infarction | Coronary DiseaseItaly
-
Aarhus University Hospital SkejbyDanish Heart FoundationCompletedPrimary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 HoursAcute Myocardial InfarctionDenmark
-
Atrium Medical CorporationCompletedAcute Anterior Myocardial InfarctionUnited States, Germany, United Kingdom, Austria, Netherlands, Poland